RCS - Frontier IP Group - CRIL wins EUR140,000 EU Graphene Flagship funding

Frontier IPAnnouncement

17/02/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200217:nRSQ1331Da

RNS Number : 1331D  Frontier IP Group plc  17 February 2020

RNS REACH

AIM: FIPP

17 February 2020

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Cambridge Raman Imaging wins €140,000 EU Graphene Flagship
funding

 

Frontier IP, a specialist in commercialising university intellectual property,
today announces that portfolio company Cambridge Raman Imaging Limited  (the
"Company") has been awarded €140,000 by the European Union's Graphene
Flagship to accelerate development of its innovative graphene-enabled scanning
Raman microscope.

 

The Company, a spin out from the University of Cambridge and the Politecnico
di Milano in Italy, was incorporated in March 2018 to develop and
commercialise the joint work of both universities to create graphene-based
ultra-fast lasers. Frontier IP owns 33.3 per cent of the Company.

 

Cambridge Raman Imaging is initially developing a Raman-imaging scanning
microscope to diagnose and track tumors, and for other detection applications.

 

The technology uses graphene to modulate ultra-short pulses of light that can
be synchronised in time and are much lower cost than conventional systems.

 

The Company's scanning microscope will target real-time digital images of
fresh tissue samples to detect and show the extent of tumours, their response
to drug treatments and to allow surgeons to see if a cancer has been
completely removed.

 

Existing histopathology technologies mean samples taken from a patient must be
stained and sent to a laboratory for analysis, including during operations.
Cambridge Raman Imaging's lasers will be compact enough to use in an operating
theatre, speeding up progress. The global market size for tumour analysis and
tracking has been estimated to be £9 billion a year, according to Grandview
Research.

 

Potential future applications include endoscopic examination, scanning body
fluids for pathogens or tumour cells, and imaging semiconductors or proteins.

 

The Graphene Flagship is one of the largest research initiatives ever funded
by the EU, tasked with bringing together academic and industrial researchers
to take graphene from academia and into society.

 

Paul Mantle, Cambridge Raman Imaging director, said: "This technology has the
potential to revolutionise patient care by giving the clinician accurate
information on tumour type and response to treatment."

 

Neil Crabb, chief executive officer of Frontier IP Group, said: "Cambridge
Raman Imaging is our first spin out to develop a graphene-based technology.
Although the first applications are in healthcare, we believe there could be
broader applications in other industries. We're delighted the EU Graphene
Flagship recognises the potential of the technology with the grant award to
accelerate its development "

 

ENQUIRIES

 Frontier IP Group Plc                                              T: 020 7332 2338
 Neil Crabb, Chief Executive
 Andrew Johnson, Communications & Investor Relations                M: 07464 546 025
 Group website: www.frontierip.co.uk (http://www.frontierip.co.uk)
 Allenby Capital Limited (Nominated Adviser)                        T: 0203 328 5656
 Nick Athanas / Nicholas Chambers

 

ABout frontier IP

Frontier IP unites science, finance and industry by identifying strong
intellectual property and accelerating its development through a range of
commercialisation services. A critical part of the Group's work is involving
relevant industry partners at an early stage of development to ensure
technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence
income by taking an active involvement in spin-out companies, including
support for fund raising and collaboration with relevant industry partners at
an early stage of development.

ABOUT THE GRAPHENE FLAGSHIP

The Graphene Flagship is research, innovation and collaboration.

 

Funded by the European Commission, the Graphene Flagship aims to secure a
major role for Europe in the ongoing technological revolution, helping to
bring graphene innovations out of the lab and into commercial applications.
The Graphene Flagship gathers nearly 150 academic and industrial partners from
23 countries, all exploring different aspects of graphene and related
materials. Bringing diverse competencies together, the Graphene Flagship
facilitates cooperation between its partners, accelerating the timeline for
industry acceptance of graphene technologies. The European Commission's FET
Flagships enable research projects on an unprecedented scale. With €1
billion budgets, the Graphene Flagship, Human Brain Project and Quantum
Flagship serve as technology accelerators, helping Europe to compete with
other global markets in research and innovation.

 

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM quoted)
companies to distribute media only / non-regulatory news releases into the
public domain.   Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be disseminated
as an RNS regulatory announcement and not on RNS Reach.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  NRABRGDDLUBDGGL